Preparation of poly-lactic acid microspheres containing the angiogenesis inhibitor TNP-470 with medium-chain triglyceride and the in vitro evaluation of release profiles

By Kakinoki S.   Yasuda C.   Kaetsu I.   Uchida K.   Yukutake K.   Nakayama M.   Fujiie S.   Kuroda D.   Kato M.   Ohyanagi H.  

European Journal of Pharmaceutics and Biopharmaceutics, Vol. 55, Iss. 2, 2003-03 ,pp. : 155-160

Elsevier

Access to resources Recommend Favorite

Vatalanib: the clinical development of a tyrosine kinase inhibitor of angiogenesis in solid tumours

By Scott Edwina N   Meinhardt Gerold   Jacques Christian   Laurent Dirk   Thomas Anne L  

Expert Opinion on Investigational Drugs, Vol. 16, Iss. 3, 2007-03 ,pp. : 367-379

Informa Healthcare

Access to resources Recommend Favorite

Clinical Development of Angiogenesis Inhibitors to Vascular Endothelial Growth Factor and Its Receptors as Cancer Therapeutics

By  

Current Cancer Drug Targets, Vol. 2, Iss. 2, 2002-06 ,pp. : 135-156

Bentham Science Publishers

Access to resources Recommend Favorite

Development of a membrane-targeted complement inhibitor for clinical use

By Dodd I.   Oldroyd R.G.   Powell S.   Affleck L.J.   Bamber L.   Gallagher S.   Rowling P.J.E.   Ragnauth C.   Smith G.P.   Pratt J.R.   Sacks S.H.   Linton S.M.   Morgan B.P.   Smith R.A.G.  

Immunopharmacology, Vol. 49, Iss. 1, 2000-08 ,pp. : 63-63

Elsevier

Access to resources Recommend Favorite

Marimastat: the clinical development of a matrix metalloproteinase inhibitor

By Thomas A.L.   Steward W.P.  

Expert Opinion on Investigational Drugs, Vol. 9, Iss. 12, 2000-12 ,pp. : 2913-2922

Informa Healthcare

Access to resources Recommend Favorite